Evommune, Inc.
EVMNHeld by 5 specialist biotech funds
High Convergence5 funds opened new positions. Next phase2 readout (EVO756): Jul 2026. Short interest: 17.6% of float.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.